A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up

Transplantation

Volumn 94, Issue 3, 2012, Pages

  Tydén, Gunnar ^a   Ekberg, Henrik ^b   Tufveson, Gunnar ^c   Mjörnstedt, Lars ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PLACEBO; RITUXIMAB;

BLOOD GROUP ABO INCOMPATIBILITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; LONG TERM SURVIVAL; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; PLACEBOS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864655397     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000418580.88642.e1     Document Type: Letter

References (5)

1. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximax. Transplantation 2003; 76: 730.
2. Genberg H, Kumlien G,Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximabVa three-year follow-up. Transplantation 2008; 85: 1745.
3. Tydén G, Genberg H, Tollemar J, et al. A randomized, double-blind, placebocontrolled study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
4. Kamar N, Miloto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2009; 10: 89.
5. Kyaw T, Tay C, Krishnamurthi S, et al. B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2001; 109: 830.